Clinical Trial

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

Study acronym: REGENERATE-PD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Protocol Amendment History 34 amendments
This ClinicalTrials.gov record has been amended 34 times since 2024-02-23; most recent amendment 2026-06-25.
Status change: Not Yet Recruiting → Recruiting 2024-06-20
Trial Details
NCT Number NCT06285643
Lead Sponsor AskBio Inc
Collaborators: Bayer
Conditions Parkinson Disease
Enrollment 127 participants
Start Date 2024-06-11
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-29